Halozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year High – What’s Next?

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $104.96 and last traded at $104.8050, with a volume of 848025 shares changing hands. The stock had previously closed at $103.00.

Analysts Set New Price Targets

HALO has been the topic of a number of recent research reports. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, August 14th. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. TD Cowen upped their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Stock Up 2.6%

The company’s 50-day moving average is $81.71 and its 200 day moving average is $73.26. The company has a market capitalization of $12.21 billion, a PE ratio of 32.13, a P/E/G ratio of 0.42 and a beta of 0.85. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. During the same period in the previous year, the company earned $1.54 earnings per share. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $79,987,320.40. This represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 64,103 shares of company stock valued at $5,226,496. 2.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Several large investors have recently bought and sold shares of the business. MidFirst Bank bought a new position in Halozyme Therapeutics during the 2nd quarter valued at about $27,000. Larson Financial Group LLC grew its stake in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Halozyme Therapeutics in the second quarter worth approximately $28,000. Measured Wealth Private Client Group LLC raised its holdings in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Halozyme Therapeutics during the second quarter valued at approximately $30,000. 97.79% of the stock is currently owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.